Summit appoints Leopoldo Zambeletti as Non-Executive Director

30 May 2014

UK-based drug discovery and development company Summit (AIM: SUMM) has announced the appointment of Mr Leopoldo Zambeletti as a Non-Executive Director.

“On behalf of the Board, I am delighted to welcome Leopoldo Zambeletti to Summit’s Board of Directors,” said Dr Frank Armstrong, Non-Executive Chairman of Summit. “Leopoldo is a highly respected and experienced strategic advisor to the life sciences sector and brings significant expertise in a range of areas. We look forward to him contributing to the future strategy of Summit as we focus on advancing our two independent programmes developing potential life-changing treatments for DMD and CDI.”

Mr Zambeletti is an independent strategic advisor to the life sciences sector with expertise in a range of areas including mergers and acquisitions, equity financing and product out-licensing. Mr Zambeletti previously worked in investment banking for 19 years where he led the European Healthcare Investment teams at JP Morgan and Credit Suisse respectively.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK